Zindoxifene

Zindoxifene
Clinical data
Other names	D-16726; NSC-341952
Identifiers
	IUPAC name [4-(5-Acetyloxy-1-ethyl-3-methylindol-2-yl)phenyl] acetate;
CAS Number	86111-26-4;
PubChem CID	65645;
ChemSpider	59082;
UNII	1IRS95M8DN;
KEGG	C14745;
ChEBI	CHEBI:35052;
ChEMBL	ChEMBL32227;
CompTox Dashboard (EPA)	DTXSID60235396 ;
Chemical and physical data
Formula	C21H21NO4
Molar mass	351.402 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1C2=C(C=C(C=C2)OC(=O)C)C(=C1C3=CC=C(C=C3)OC(=O)C)C;
	InChI InChI=1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3; Key:KSZGVNZSUJHOJA-UHFFFAOYSA-N;

Zindoxifene (INN; former developmental code names D-16726, NSC-341952) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development in the 1980s and early 1990s for the treatment of breast cancer but was not marketed.^[1] It showed estrogenic-like activity in preclinical studies and failed to demonstrate effectiveness as a treatment for breast cancer in clinical trials.^[2]^[3] Zindoxifene was the lead compound of the distinct 2-phenylindole class of SERMs,^[4]^[5] and the marketed SERM bazedoxifene was derived from the major active metabolite of zindoxifene, D-15414.^[2]^[3] Zindoxifene was first described in 1984.^[1]